BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka I, Chakraborty A, Saulnier O, Benoit-Pilven C, Vacher S, Labiod D, Lam EWF, Bièche I, Delattre O, Pouzoulet F, Auboeuf D, Vagner S, Dutertre M. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res 2020;48:2676-93. [PMID: 31943118 DOI: 10.1093/nar/gkz1213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Du JX, Zhu GQ, Cai JL, Wang B, Luo YH, Chen C, Cai CZ, Zhang SJ, Zhou J, Fan J, Zhu W, Dai Z. Splicing factors: Insights into their regulatory network in alternative splicing in cancer. Cancer Lett 2021;501:83-104. [PMID: 33309781 DOI: 10.1016/j.canlet.2020.11.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel) 2021;10:349. [PMID: 33652780 DOI: 10.3390/antiox10030349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
3 Zhang B, Wu Q, Cheng S, Li W. Systematic Profiling of mRNA Splicing Reveals the Prognostic Predictor and Potential Therapeutic Target for Glioblastoma Multiforme. J Oncol 2021;2021:4664955. [PMID: 34326872 DOI: 10.1155/2021/4664955] [Reference Citation Analysis]
4 Wang H, Liu H, Li J, Wei S, Liu X, Wan H, Zheng P, Zheng H. Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention. Onco Targets Ther 2020;13:12905-18. [PMID: 33376345 DOI: 10.2147/OTT.S275725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ashrafizadeh M, Saebfar H, Gholami MH, Hushmandi K, Zabolian A, Bikarannejad P, Hashemi M, Daneshi S, Mirzaei S, Sharifi E, Kumar AP, Khan H, Heydari Sheikh Hossein H, Vosough M, Rabiee N, Thakur Kumar V, Makvandi P, Mishra YK, Tay FR, Wang Y, Zarrabi A, Orive G, Mostafavi E. Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: Stimuli-responsive carriers, co-delivery and suppressing resistance. Expert Opin Drug Deliv 2022. [PMID: 35152815 DOI: 10.1080/17425247.2022.2041598] [Reference Citation Analysis]
6 Mehterov N, Kazakova M, Sbirkov Y, Vladimirov B, Belev N, Yaneva G, Todorova K, Hayrabedyan S, Sarafian V. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy. Genes (Basel) 2021;12:1085. [PMID: 34356101 DOI: 10.3390/genes12071085] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Noblejas-López MDM, López-Cade I, Fuentes-Antrás J, Fernández-Hinojal G, Esteban-Sánchez A, Manzano A, García-Sáenz JÁ, Pérez-Segura P, La Hoya M, Pandiella A, Győrffy B, García-Barberán V, Ocaña A. Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer. Cancers (Basel) 2021;13:4118. [PMID: 34439272 DOI: 10.3390/cancers13164118] [Reference Citation Analysis]
8 Long J, Liu L, Zhou X, Lu X, Qin L, Ding X. HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/7130634] [Reference Citation Analysis]
9 Reviejo M, Soto M, Lozano E, Asensio M, Martínez-Augustin O, Sánchez de Medina F, Marin JJG. Impact of alternative splicing on mechanisms of resistance to anticancer drugs. Biochem Pharmacol 2021;193:114810. [PMID: 34673012 DOI: 10.1016/j.bcp.2021.114810] [Reference Citation Analysis]
10 Biswas B, Chaaban R, Chakraborty S, Devaux A, Dian AL, Minello A, Singh JK, Vagner S, Uguen P, Lambert S, Dutertre M, Carreira A. At the crossroads of RNA biology, genome integrity and cancer. Bull Cancer 2022:S0007-4551(22)00118-7. [PMID: 35597618 DOI: 10.1016/j.bulcan.2022.02.014] [Reference Citation Analysis]
11 Wang X, Yan J, Shen B, Wei G. Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells. Front Cell Dev Biol 2021;9:708066. [PMID: 34395436 DOI: 10.3389/fcell.2021.708066] [Reference Citation Analysis]
12 Cao C, Han P, Liu L, Tang Y, Tian S, Zhang K, Shi L, Liu Z, Zhuo D, Ge W, Gong W. Epithelial cell transforming factor ECT2 is an important regulator of DNA double-strand break repair and genome stability. J Biol Chem 2021;297:101036. [PMID: 34343566 DOI: 10.1016/j.jbc.2021.101036] [Reference Citation Analysis]
13 Blijlevens M, Li J, van Beusechem VW. Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities. Int J Mol Sci 2021;22:5110. [PMID: 34065983 DOI: 10.3390/ijms22105110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Marima R, Francies FZ, Hull R, Molefi T, Oyomno M, Khanyile R, Mbatha S, Mabongo M, Owen Bates D, Dlamini Z. MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets. Biomedicines 2021;9:1818. [PMID: 34944633 DOI: 10.3390/biomedicines9121818] [Reference Citation Analysis]